Comparative effectiveness of ceftriaxone in combination with a macrolide compared with ceftriaxone alone for pediatric patients hospitalized with community-acquired pneumonia

Pediatric Infectious Disease Journal

Volumn 33, Issue 4, 2014, Pages 387-392

  Leyenaar, Jo Anna K ^a   Shieh, Meng Shiou ^b   Lagu, Tara ^a,b   Pekow, Penelope S ^b,c   Lindenauer, Peter K ^a,b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BAYSTATE MEDICAL CENTER   (United States)

^c UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

Adolescent; Antibiotics; Child; Community acquired pneumonia; Comparative effectiveness

Indexed keywords

AZITHROMYCIN; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CEFTRIAXONE; CLARITHROMYCIN; ERYTHROMYCIN; STEROID; ANTIINFECTIVE AGENT; MACROLIDE;

ADOLESCENT; ANTIBIOTIC THERAPY; ARTICLE; CHILD; COHORT ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; COMPARATIVE EFFECTIVENESS; FEMALE; HOSPITAL COST; HOSPITAL PATIENT; HOSPITAL READMISSION; HOSPITALIZATION; HOSPITALIZED CHILD; HUMAN; INTENSIVE CARE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYCOPLASMA PNEUMONIAE; POINT OF CARE TESTING; PRIORITY JOURNAL; PRIVATE HEALTH INSURANCE; PROPENSITY SCORE; TREATMENT OUTCOME; COMMUNITY-ACQUIRED INFECTIONS; DRUG COMBINATION; ECONOMICS; INFANT; PNEUMONIA, BACTERIAL; PRESCHOOL CHILD; RETROSPECTIVE STUDY; UNITED STATES;

ADOLESCENT; ANTI-BACTERIAL AGENTS; CEFTRIAXONE; CHILD; CHILD, PRESCHOOL; COMMUNITY-ACQUIRED INFECTIONS; DRUG THERAPY, COMBINATION; HOSPITAL COSTS; HUMANS; INFANT; LENGTH OF STAY; MACROLIDES; PNEUMONIA, BACTERIAL; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 84897023667     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000119     Document Type: Article

References (33)

1. McIntosh K. Community-Acquired pneumonia in children. N Engl J Med. 2002;346:429-437.
2. Eslamy HK, Newman B. Pneumonia in normal and immunocompromised children: An overview and update. Radiol Clin North Am. 2011;49:895-920.
3. Elixhauser A. HCUP Statistical Brief #56. July 2008. Agency for Healthcare Research and Quality, Rockville, MD. AHRQ Hospital Stays for Children. 2006. Available at: Http://www.hcup-us.ahrq.gov/reports/statbriefs/ sb56.jsp. Accessed February 1, 2012.
4. HCUPnet. Healthcare Cost and Utilization Project (HCUP). 2009. Agency for Healthcare Research and Quality, Rockville, MD. Available at: Http:// hcupnet.ahrq.gov/ Accessed June 20, 2012.
5. Michelow IC, Olsen K, Lozano J, et al. Epidemiology and clinical characteristics of community-Acquired pneumonia in hospitalized children. Pediatrics. 2004;113:701-707.
6. Kogan R, Martínez MA, Rubilar L, et al. Comparative randomized trial of azithromycin versus erythromycin and amoxicillin for treatment of community-Acquired pneumonia in children. Pediatr Pulmonol. 2003;35:91-98.
7. Principi N, Esposito S. Emerging role of Mycoplasma pneumoniae and Chlamydia pneumoniae in paediatric respiratory-Tract infections. Lancet Infect Dis. 2001;1:334-344.
8. Principi N, Esposito S, Blasi F, et al.; Mowgli study group. Role of Mycoplasma pneumoniae and Chlamydia pneumoniae in children with community-Acquired lower respiratory tract infections. Clin Infect Dis. 2001;32:1281-1289.
9. Mullholland S, Gavranich J, Chang AB. Antibiotics for community-Acquired lower respiratory tract infections secondary to Mycoplasma pneumoniae in children. Cochrane Database Syst Review. 2010;7:CD004875.
10. Bradley JS, Byington CL, Shah SS, et al. The management of communityacquired pneumonia in infants and children older than 3 months of age: Clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis. 2011;53:e25-e76.
11. Lindenauer PK, Pekow PS, Lahti MC, et al. Association of corticosteroid dose and route of administration with risk of treatment failure in acute exacerbation of chronic obstructive pulmonary disease. JAMA. 2010;303: 2359-2367.
12. Lindenauer PK, Rothberg MB, Pekow PS, et al. Outcomes of care by hospitalists, general internists, and family physicians. N Engl J Med. 2007;357:2589-2600.
13. Rothberg MB, Pekow PS, Lahti M, et al. Antibiotic therapy and treatment failure in patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease. JAMA. 2010;303:2035-2042.
14. Feudtner C, Dai D, Hexem KR, et al. Prevalence of polypharmacy exposure among hospitalized children in the United States. Arch Pediatr Adolescent Med. 2012;166:9-16.
15. McLeod L, French B, Dai D, et al. Patient volume and quality of care for young children hospitalized with acute gastroenteritis. Arch Pediatr Adolesc Med. 2011;165:857-863.
16. Lasky T, Greenspan J, Ernst FR, et al. Pediatric vancomycin use in 421 hospitals in the United States, 2008. PLoS One. 2012;7:e43258.
17. Aronsky D, Haug PJ, Lagor C, et al. Accuracy of administrative data for identifying patients with pneumonia. Am J Med Qual. 2005;20:319-328.
18. Feudtner C, Christakis DA, Connell FA. Pediatric Deaths Attributable to Complex Chronic Conditions: A population based study of Washington State: 1980-1997. Pediatrics. 2000;106:205-209.
19. Ambroggio L, Taylor JA, Tabb LP, et al. Comparative effectiveness of empiric β-lactam monotherapy and β-lactam-macrolide combination therapy in children hospitalized with community-Acquired pneumonia. J Pediatr. 2012;161:1097-1103.
20. Bradley JS, Arguedas A, Blumer JL, et al. Comparative study of levofloxacin in the treatment of children with community-Acquired pneumonia. Pediatr Infect Dis J. 2007;26:868-878.
21. Esposito S, Cohen R, Domingo JD, et al. Antibiotic therapy for pediatric community-Acquired pneumonia: Do we know when, what and for how long to treat? Pediatr Infect Dis J. 2012;31:e78-e85.
22. Yamada M, Buller R, Bledsoe S, et al. Rising rates of macrolide-resistant Mycoplasma pneumoniae in the central United States. Pediatr Infect Dis J. 2012;31:409-400.
23. Kronman AMP, Hersh AL. Ambulatory visit rates and antibiotic prescribing for children with pneumonia, 1994-2007. Pediatrics. 2011;127:411-418.
24. Wang K, Gill P, Perera R, et al. Clinical symptoms and signs for the diagnosis of Mycoplasma pneumoniae in children and adolescents with community-Acquired pneumonia. Cochrane Database Syst Rev. 2012;10:CD009175.
25. Hersh AL, Shapiro DJ, Pavia AT, et al. Antibiotic prescribing in ambulatory pediatrics in the United States. Pediatrics. 2011;128:1053-1061.
26. Bundy DG. Hospitalizations with primary versus secondary discharge diagnoses of asthma: Implications for pediatric asthma surveillance. J Pediatr. 2007;150:446-9, 449.e1.
27. Cameron EJ, McSharry C, Chaudhuri R, et al. Long-Term macrolide treatment of chronic inflammatory airway diseases: Risks, benefits and future developments. Clin Exp Allergy. 2012;42:1302-1312.
28. Steel HC, Theron AJ, Cockeran R, et al. Pathogen-And host-directed anti-inflammatory activities of macrolide antibiotics. Mediators Inflamm. 2012;2012:584262.
29. Kovaleva A, Remmelts HH, Rijkers GT, et al. Immunomodulatory effects of macrolides during community-Acquired pneumonia: A literature review. J Antimicrob Chemother. 2012;67:530-540.
30. Richeldi L, Ferrara G, Fabbri LM, et al. Macrolides for chronic asthma. Cochrane Database Syst Review. 2005;4:CD002997.
31. Brusselle GG, Vanderstichele C, Jordens P, et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): A multicentre randomised double-blind placebo-controlled trial. Thorax. 2013;68:322-329.
32. Mikailov A, Kane I, Aronoff SC, et al. Utility of adjunctive macrolide therapy in treatment of children with asthma: A systematic review and metaanalysis. J Asthma Allergy. 2013;6:23-29.
33. Koutsoubari I, Papaevangelou V, Konstantinou GN, et al. Effect of clarithromycin on acute asthma exacerbations in children: An open randomized study. Pediatr Allergy Immunol. 2012;23:385-390.